CJC-1295 10mg

CJC-1295 10mg Lyophilized Powder: Biochemical Mechanism, Research Applications, and Analytical Guide

CJC-1295 10mg is a synthetic, 29-amino acid tetrasubstituted peptide analog of Growth Hormone-Releasing Hormone (GHRH). Derived from the functional GRF(1-29) fragment, CJC-1295 is engineered with four targeted amino acid substitutions that protect the peptide chain from rapid enzymatic degradation by plasma proteases like dipeptidyl peptidase-4 (DPP-4). By selectively binding to GHRH receptors on anterior pituitary somatotrophs, CJC-1295 stimulates endogenous production and release of Growth Hormone (GH) and downstream Insulin-Like Growth Factor 1 (IGF-1).

Key Features & Technical Specifications

 Sequence & Formula: C_{152}H_{252}N_{44}O_{42} | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg

 Molecular Mass: ~3,367.99 g/mol

 Form & Quality: 10mg lyophilized sterile cake; high-purity (≥99% HPLC certified)

 Primary Mechanism: Direct GHRH receptor agonism

 Solubility & Handling: Soluble in bacteriostatic water or sterile saline protocols

Primary Research Areas & Proposed Benefits

 Lean Tissue & Muscle Mass: Activation of the GH/IGF-1 signaling cascade enhances cellular protein synthesis, promoting muscle cell proliferation and hypertrophy in model systems.

 Enhanced Lipolysis: Elevating circulating growth hormone accelerates lipid mobilization and beta-oxidation, leading to reductions in visceral and subcutaneous fat tissue.

 Connective Tissue Repair: IGF-1 upregulates collagen production, aiding cellular replication for tendon, ligament, and skeletal muscle recovery.

 Sleep Architecture & Metabolic Vitality: Elevated GHRH receptor activity reinforces deep slow-wave sleep cycles, supporting cellular restoration and systemic vitality.

Synergistic Peptide Research: CJC-1295 + Ipamorelin

In laboratory research workflows, CJC-1295 No DAC is often combined with Ipamorelin (a selective growth hormone secretagogue receptor agonist). While CJC-1295 acts directly on GHRH receptors, Ipamorelin targets ghrelin/GHS-R1a receptors while simultaneously suppressing somatostatin, yielding a synergistic GH release significantly higher than either compound alone.